Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.

Scroll Top